The goal of this study was to compare the performance of several measures of carotid intima-media thickness (C-IMT) as predictors of cardiovascular events (CVEs), and to investigate whether they add to the predictive accuracy of Framingham risk factors (FRFs).
Risk assessment in primary prevention is usually based on vascular risk factors (VRFs), but the current ability to predict new cardiovascular events (CVEs) remains limited, even using the "global risk assessment approach" (1) . Carotid artery intima-media thickness (C-IMT), measured by B-mode ultrasound, is a recognized marker of carotid and coronary atherosclerosis (2), although it is still debated whether C-IMT improves the predictive capacity of VRFs (3) (4) (5) (6) (7) (8) (9) (10) (11) .
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Other uncertainties include identification of the most informative segment (common carotid, bifurcation, or internal carotid arteries) and/or the best summary measure (mean, max, or mean-max).
Interadventitia common carotid artery diameter (ICCAD), assessed in plaque-free areas, is another variable easily measurable by B-mode ultrasound. ICCAD increases during atherogenesis (12) , and this enlargement is associated with VRFs (13) and subclinical atherosclerosis (14, 15) . On the basis of these premises, it can be hypothesized that, like C-IMT, ICCAD may improve risk assessment in asymptomatic individuals. Studies specifically designed to assess the prognostic value of ICCAD are few (9,16 -18) . To the best of our knowledge, only 1 study measured the predictive capacity of the combination of C-IMT and ICCAD (9) .
All the aforementioned issues have been addressed in IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population), a cohort study carried out in 5 European countries (19) . We performed a systematic analysis to compare the performance of 11 different C-IMT variables measured at baseline, as predictors of subsequent CVEs. In addition, we investigated: 1) whether ICCAD is a predictor of future CVEs independently of C-IMT; and 2) whether C-IMT variables, ICCAD, or their combinations significantly add to the predictive accuracy of standard models for cardiovascular risk stratification.
Methods
Participants. The design, objectives, methods, eligibility criteria, and baseline evaluation of the IMPROVE study were reported in the text and online material of Baldassarre et al. (19) . Briefly, 3,711 individuals (age 54 to 79 years) with at least 3 VRFs, free from cardiovascular and cerebrovascular disease, were enrolled in 7 centers in Finland, France, Italy, the Netherlands, and Sweden (details in the Online Appendix). The measure of carotid diameter was not available for 8 individuals, so this report refers to 3,703 subjects. Carotid ultrasound examination. Seven identical machines (Technos, Esaote, Genoa, Italy) equipped with a 5-to 10-MHz linear array probe were used. All machines were calibrated with a phantom at baseline and checked after 1 year. The far walls of the left and right common carotids, bifurcations, and internal carotid arteries were visualized at 3 scan angles (lateral, anterior, and posterior) and recorded on S-VHS videotapes. Each segment was measured in at least 3 different frames. ICCAD was measured in the second centimeter of the common carotid proximal to the bifurcation. All measurements were made in the Milan center using dedicated software (M'Ath, Metris SRL, Argenteuil, France) (20) . The list of ultrasonographic variables considered, with definitions and precision metrics, are shown in Table 1 . Anatomical locations are shown in Online Figure 1 . Spearman correlations between ultrasonographic variables were all significant (all p Ͻ 0.0001) (Online Table 1 ).
As shown in Online Figure 1 , plaques were incorporated in IMT measurements. However, to assess the potential incremental prognostic value of plaque, IMT variables were also measured after excluding plaques (defined as IMT max Ͼ1.5).
The variable "presence of at least 1 plaque" was recorded. Cardiovascular events. The occurrence of CVEs (myocardial infarction, sudden cardiac death, angina pectoris, ischemic stroke, transient ischemic attack, new diagnosis of intermittent claudication, heart failure, or any surgical intervention or revascularization of coronary or peripheral arteries) was assessed at months 15, 30 , and at the end of follow-up. Carotid surgical or endovascular procedures were not included among endpoints, as these procedures might be directly related to the qualifying carotid ultrasound investigation at study entry or during follow-up. Angina pectoris, myocardial infarction, and ischemic stroke were diagnosed according to European Society of Cardiology guidelines (21, 22) . All events were validated by local specialists through medical records and death certificates. Copies of documents were sent to a designated specialist (U.d.F.), who was unaware of clinical history and C-IMT data, for adjudication.
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All statistical tests were 2-sided at a level of significance of 0.05 or 0.01, as indicated. The Bonferroni method was applied to account for multiple comparisons. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina). Reclassification statistics were assessed with the SAS macros published by Cook and Ridker (23) .
Results
Baseline characteristics of participants with and without CVEs are shown in Table 2 . Mean age was 64.2 years, and 47.9% of subjects were males. A total of 514 (13.9%) participants were free of relevant pharmacological treatments. Follow-up and cardiovascular events. Over a median follow-up of 36.2 months (interquartile range: 35.8 to 37.4), 215 CVEs occurred (incidence per 1,000 person-years ϭ 19.9): 125 CVEs were coronary, 73 cerebrovascular, and 17 peripheral. Number of subjects lost to follow-up was 238 (6.4%) (details of CVEs and those lost to follow-up are in the Online Appendix). C-IMT, ICCAD, and risk of combined endpoint. All measures of C-IMT and ICCAD were significantly associated with the risk of combined CVEs ( Table 4 . Age-and sex-adjusted standardized HRs ranged from 1.19 to 2.51 and were generally higher for cerebrovascular endpoints. No significant interaction between ultrasonographic variables and type of vascular event was found, with p values of Model 3 ranging from 0.237 to 0.900.
Online Table 2 shows the same analysis as in Table 4 , but restricted to "hard clinical events." Although no significant association with hard coronary events was detected, most of the measures of C-IMT and ICCAD remained significantly Table 5 show that IMT mean and IMT mean-max , and their combination with ICCAD, performed better than CC-IMT mean (the IMT variable most widely used in ultrasonographic studies). The NRI using these variables ranged from 10.7% (IMT mean ) to 20.1% (ICCAD ϩ IMT max ). When the analysis was repeated considering coronary or cerebrovascular endpoints, composite IMT variables performed better than CC-IMT mean in the reclassification of cerebrovascular events, but not in reclassification of coronary events. Regardless of the type of endpoint considered, models with the combination ICCAD ϩ IMT mean or IMT mean-max always performed significantly better than CC-IMT mean . Table 6 shows that in IDI analysis, the variable "Presence of at least 1 plaque," defined as IMT max Ͼ1.5, performed significantly better than IMT mean only when the latter was measured in plaque-free areas; otherwise, the predictive value of the plaque presence alone was always significantly worse. Incremental value of C-IMT with respect to FRFs. The combination of IMT variables or ICCAD with FRFs added little to the overall risk discrimination based on FRFs alone in receiver-operating characteristic (ROC) analyses (all p values Ͼ0.05), but performed significantly better than FRFs alone in reclassification analyses (Table 7) . In most cases, IDI values reached statistical significance even after Bonferroni correction. The combination of FRFs plus composite IMTs plus ICCAD provided the highest score in risk ACE ϭ angiotensin-converting enzyme; BMI ϭ body mass index; CHD ϭ coronary heart disease; HDL ϭ high-density lipoprotein; hs-CRP ϭ high-sensitivity C-reactive protein; LDL ϭ low-density lipoprotein; other abbreviations as in Table 1 .
classification. The further inclusion of plaque presence increased NRI from 12.1% to 13.0%. The use of the FRS in place of FRFs in reclassification analyses provided similar results (data not shown). Table 8 shows the estimated 10-year CVE risk categories according to FRFs before and after adding ICCAD and IMT mean-max . The overall NRI was 12% (p ϭ 0.003), and 35.9% of subjects at intermediate risk were reclassified.
Sex differences.
Men and women differed in mean values for many baseline variables (data not shown), but no significant interactions with sex were found in any of the analyses presented.
Discussion
In this study of Europeans with at least 3 VRFs, but no overt cardiovascular or cerebrovascular disease, we found 
Figure 1 FRS-Adjusted Kaplan-Meier Incidence Curves
The study population was stratified according to IMT mean-max and ICCAD values above or below their respective medians (1.34 mm and 7.74 mm, respectively). Curves were computed for the mean value of FRS (22.6%). FRS ϭ Framingham Risk score; ICCAD ϭ interadventitia common carotid artery diameter; IMT mean-max ϭ mean-maximum intima-media thickness. Tables 1 and 3 .
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or cerebrovascular events are considered. In line with the ARIC study (30) , CC-IMT was as good as composite IMT variables in improving the prediction of coronary events (Tables 4 and 5) . A possible explanation is that the presence of atherosclerosis in the bifurcation or in the internal carotid may actually cause cerebrovascular events, whereas it is merely a marker of coronary atherosclerosis. Interestingly, in reclassification analyses, composite IMTs that incorporate plaques in their measurement performed significantly better than the presence of plaque. ICCAD as predictor of vascular events. Compared with CC-IMT alone, the best reclassification was obtained by combining IMT mean-max and ICCAD. The NRI using this combination was Ͼ19% for combined and cerebrovascular events and 9.8% for coronary events. Although prospective studies (31) suggest a role for IMT as a predictor of myocardial infarction and stroke, evidence on the predictive capacities of ICCAD is sparse. Two studies reported that IMT is a predictor of CVEs independently of lumen diameter (32, 33) . Only 1 large population study (9) showed that even after adjusting for IMT and VRFs, right ICCAD was significantly associated with incident cardiac events. We also found the highest estimated cumulative incidence of events in subjects having both diameter enlargement and increased IMT. Despite this, Eigenbrodt et al. (9) reported that on the basis of ROC analyses, carotid diameter measures added little to overall risk discrimination, especially after VRF adjustment (9). Our own ROC curve analysis (Table 7) agrees with this finding, but using IDI statistics, the inclusion of ICCAD into a model based on FRFs significantly added to the overall risk discrimination. C-IMTs and ICCAD are independent biomarkers of atherosclerosis. The fact that C-IMTs and ICCAD predict the risk of CVEs independently of each other, together with the finding that these variables are associated with different VRFs (14, 34) , suggests that IMTs and ICCAD represent independent arterial responses to different pathophysiological mechanisms. C-IMT assesses atherosclerosis, depending on whether atherosclerotic plaques are incorporated in IMT measurements or not. When plaques are incorporated, as in our case, IMT reflects atherosclerosis (27, 35) . Arterial diameter enlargement reflects at least 2 processes. The first is vascular remodeling in response to the Tables 1, 3 , and 5.
growth of local atherosclerotic plaques (36) . The second, as measured in our study, is independent of the presence of focal atherosclerosis (being measured in plaque-free areas); this occurs as a compensatory response to VRFs (13, 14) and associates fairly well with the coronary artery disease status (17) . On this basis, it can be concluded that IMTs and ICCAD provide additional information on atherosclerotic burden, thus supporting the concept of their potential usefulness as independent biomarkers of this multifactorial disease. Our observation that individuals with an average FRS have a 6.5% risk of developing a first CVE over 3 years if their IMT mean-max and ICCAD are high, versus a 3.4% risk if these variables are low (Fig. 1) , supports this concept. C-IMTs, plaque, and ICCAD add predictive value to FRFs. It is also important to know whether C-IMT and/or ICCAD provide prognostic information for individuals over and above that provided by FRFs: the fact that these variables are significant and independent predictors of CVEs does not necessarily mean they will be useful in the clinic. This may be 1 reason for the reluctance of the medical community to adopt C-IMT as a clinical tool (18) . Most of the authors using the ROC metric to address this topic (3) (4) (5) (6) (7) (8) (9) have concluded that the magnitude of any improvement is insufficient to change current clinical and public health efforts to reduce the burden of vascular diseases (3,6 -8) . Our own data based on ROC analyses are in line with such statements, as the addition of IMT and ICCAD to the risk models built on FRFs had marginal, nonsignificant effects on C-statistics (Table 7) . However, the C-statistic is insensitive to small changes in predictive accuracy, and even well-established VRFs may be discarded as nonsignificant in some circumstances (37, 38) . Consequently, there is general agreement that newer methods such as reclassification statistics (IDI and NRI) must be applied (37, 39) . To the best of our knowledge, only 4 studies have so far used reclassification analyses to evaluate whether ultrasound measures add prognostic information over and above traditional VRFs (10,11,30,40 ). The first (10) concluded that, in subjects from the general population, models that included C-IMT do not consistently improve individual risk stratification over those including only traditional VRFs. The second and the third (11, 30) , using data from the ARIC cohort, showed that compared with a model that includes FRFs only, the model including FRFs plus C-IMT plus information on the presence of carotid plaques provided a modest improvement in the area under the curve and a significant NRI. The last study (40) showed that the addition of C-IMT to FRFs significantly improved risk classification in women, but not in men. Our results show that substantial improvements over FRFs alone can be obtained when IMT variables are used, especially when combined with ICCAD. Therefore, our findings provide new evidence to support the use of IMT variables and ICCAD, in addition to VRFs, for cardiovascular risk stratification in clinical practice, with a NRI of 12.1%. The difference from the conclusions of the previous studies (10,11) may be due to the characteristics of the IMPROVE subjects, who were chosen to have Ն3 VRFs instead of the lower-risk general population, and the use of composite IMT variables instead of only CC-IMT. Clearly, the individual assessment of composite IMT variables and ICCAD is time consuming compared with CC-IMT assessment alone (15 to 20 vs. 8 to 10 min). However, we believe that the benefits provided by a better risk classification may easily offset the additional costs. We have shown that, focusing on the intermediate (10% to 20%) risk category, which represents the real gray decision area for many clinicians, the addition of ICCAD and IMT mean-max to a model based on FRFs allows, on average, the reclassification of 14.5% of subjects in the high-risk category (Table 8) . Improving the predictability for this group would have significant clinical implications, because it means shifting subjects with the highest chance of developing a CVE to the risk category qualified for pharmacological treatment. The cost of such strategy can be roughly estimated from the number needed to screen to prevent 1 CVE. to a higher-risk category, thus qualifying for pharmacological treatment, and in this group, the extrapolated 10-year incidence was 40.6% (100 events). Thus, assuming a treatment efficacy of 20% to 30% (41) , from 20 to 30 events could be prevented, yielding a needed to screen ranging from 57 to 85 (i.e., 1,697/30 and 1,697/20). It has to be noticed that 26.3% of the high-risk subjects were downgraded to a lower-risk category, but this does not imply that these subjects should lose their qualification for pharmacological treatments. We believe, in fact, that the use of IMT for cardiovascular risk reclassification should be applied only to patients at intermediate risk.
Strengths and limitations.
The IMPROVE study has several strengths. It examined a large number of ultrasonographic variables, which allowed us to identify the most informative segment and/or the best IMT summary measure to be used for predictive purposes. The study was conducted across 5 European countries. Methods of carotid image acquisition and measurement of C-IMT were standardized across centers (all sonographers were trained and certified, and all scans were analyzed blindly in the same reading center). With follow-up data obtained on 93.7% of patients, our results were minimally affected by "loss to follow-up" bias. Finally, the analyses were adjusted for many potential confounders not considered in previous studies, for example, pharmacological treatments. There are also potential limitations. The findings can only be extrapolated cautiously to the general European population or to patients with fewer than 3 VRFs. However, the HRs we observed are similar to those reported in other large population studies (24 -27) . Also, it remains possible that systematic differences existed between recruiting centers (19) . Finally, the low number of CVEs will have constrained the precision of estimates in the subgroups (coronary events and cerebrovascular events).
Conclusions
We conclude that C-IMT and ICCAD are independent predictors of CVEs in European high-risk individuals; these markers contribute significant incremental prediction beyond FRFs alone. A risk stratification strategy based on C-IMT and ICCAD as an adjunct to FRFs would seem to be a rational approach to the prevention of cardiovascular disease.
